Corvus Pharmaceuticals
CRVS
10.41
-0.15
-1.42%
Corvus Pharmaceuticals
US · CRVS
#3339 by market cap
Listed 2016
10.41
-0.15
-1.42%
Live - 5344 symbols - heartbeat 550s ago
· 2026-10-08 08:12
Pre-market
10.13
-2.69%
After-hours
10.52
+1.06%
- Market cap
- 875.70M
- P/E (TTM)i
- -16.27
- P/Bi
- 3.89
- EPSi
- -0.53
- Div yieldi
- 0.00%
- 52W posi
- 20%
Reader sentiment
Are you bullish or bearish on CRVS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.4 percentage points.
Institutional ownership
- Held by institutions
- 86.41% -1.42pp
- Institutions
- 202 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund40.59%
VC/PE Fund27.14%
Hedge Fund11.09%
Public Company4.99%
Individual/Insider3.54%
Private Company1.90%
Insurance Company0.39%
Government Pension Fund0.25%
Other10.06%
Top holders as of 2026-06-30
OrbiMed Advisors LLC
8.52% · 7.17M sh
BlackRock
8.49% · 7.14M sh
State Street Global Advisors
5.32% · 4.47M sh
Vanguard Capital Management, LLC
4.53% · 3.81M sh
T. Rowe Price Group, Inc.
4.50% · 3.79M sh
Adams Street Partners, LLC
3.89% · 3.28M sh
Vivo Capital, LLC
3.34% · 2.81M sh
Wellington Management Group
3.25% · 2.73M sh
Perceptive Advisors LLC
3.17% · 2.67M sh
Deep Track Capital, LP
2.96% · 2.49M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 47 buys · 2 sells
| Name | Role | Stake |
|---|---|---|
| Richard Miller | Co-Founder, President, CEO & Chairman of the Board | 2.77% |
| Leiv Lea | Chief Financial Officer | 0.34% |
| William Jones | Senior Vice President of Pharmaceutical Development | 0.21% |
| Richard van den Broek | Director | 0.19% |
| David Moore | Director | 0.03% |
| Linda Grais | Independent Director | 0.01% |
| OrbiMed Advisors LLC | -- | -- |
| Ian T. Clark | Independent Director | -- |
| Peter Thompson | Co-Founder & Independent Director | -- |
| Scott William Morrison | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-10 | Richard van den Broek | Director | Other Derivative Acquisition | +15,000 | $11.60 |
| 2026-06-10 | Linda Grais | Independent Director | Other Derivative Acquisition | +15,000 | $11.60 |
| 2026-06-10 | Ian T. Clark | Independent Director | Other Derivative Acquisition | +15,000 | $11.60 |
| 2026-06-10 | Peter Thompson | Co-Founder & Independent Director | Other Derivative Acquisition | +15,000 | $11.60 |
| 2026-06-10 | David Moore | Director | Open Market Acquisition | +21,700 | $11.53 |
| 2026-06-10 | David Moore | Director | Other Derivative Acquisition | +15,000 | $11.60 |
| 2026-05-17 | Richard Miller | Co-Founder, President, CEO & Chairman of the Board | Open Market Acquisition | +6,932 | $12.01–12.05 |
| 2026-01-27 | Peter Thompson | Co-Founder & Independent Director | Derivative Exercise and Retained | +210,000 | $0.97–15.00 |
| 2025-12-03 | Richard Miller | Co-Founder, President, CEO & Chairman of the Board | Other Derivative Acquisition | +1,000,000 | $8.81 |
| 2025-12-03 | Leiv Lea | Chief Financial Officer | Other Derivative Acquisition | +400,000 | $8.81 |
| 2025-12-03 | Jeffrey Arcara | Chief Business Officer | Other Derivative Acquisition | +100,000 | $8.81 |
| 2025-12-03 | William Jones | Senior Vice President of Pharmaceutical Development | Other Derivative Acquisition | +400,000 | $8.81 |
| 2025-10-01 | David Moore | Director | Other Derivative Acquisition | +30,000 | $7.04 |
| 2025-06-26 | OrbiMed Advisors LLC | -- | Derivative Exercise and Sale | -1,176,332 | $3.50–4.16 |
| 2025-06-26 | OrbiMed Advisors LLC | -- | Derivative Exercise and Retained | +221,352 | $3.50 |
| 2025-06-11 | Linda Grais | Independent Director | Other Derivative Acquisition | +15,000 | $4.24 |
| 2025-06-11 | Ian T. Clark | Independent Director | Other Derivative Acquisition | +15,000 | $4.24 |
| 2025-06-11 | Peter Thompson | Co-Founder & Independent Director | Other Derivative Acquisition | +15,000 | $4.24 |
| 2025-06-11 | Scott William Morrison | Independent Director | Other Derivative Acquisition | +15,000 | $4.24 |
| 2025-06-03 | William Jones | Senior Vice President of Pharmaceutical Development | Derivative Exercise and Retained | +19,357 | $3.50 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:12:11 · For reference only, not investment advice and not tailored to your situation.